Authors report a rare case of granular acute lymphoblastic leukemia (ALL) in a 45-year-old woman with a history of multiple myeloma. The patient's lymphoblasts contained large numbers of distinctive cytoplasmic granules closely mimicking heavily granulated myeloblasts in acute myeloid leukemia. These blasts were completely negative for myeloperoxidase but positive for acid phosphatase and Periodic Acid-Schiff reaction by cytochemical staining. Immunophenotype analysis by immunohistochemistry clearly demonstrated precursor B-cell phenotype. Granular ALL occurs approximately 2 to 7% in childhood populations but is extremely rare in adults. Such cases may cause problematic distinction from myeloid differentiation and lead to misdiagnosis of acute myeloid leukemia. Ten cases of adult granular acute lymphoblastic leukemia described to date in the literature were also reviewed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajh.20922 | DOI Listing |
Am J Health Syst Pharm
December 2024
The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFJ Med Econ
December 2024
Pfizer Inc., Tadworth, Surrey, United Kingdom.
Aims: Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of adult patients with mild-to-moderate COVID-19 at high risk for disease progression to severe illness. We estimated the cost-effectiveness of NMV/r versus best supportive care for 54 patient cohorts, specified according to age, vaccination status and comorbidity burden.
Materials And Methods: A previously published and validated cost-effectiveness model was utilized and adapted to the Swedish setting.
J Trauma Acute Care Surg
December 2024
From the Division of Trauma, Burn, and Surgical Critical Care, Department of Surgery (M.C.-A., C.B.S., J.C.E., C.W., S.N., R.A., Z.C., A.S., J.M.H.), Brigham and Women's Hospital, Harvard Medical School; Center for Surgery and Public Health, Department of Surgery (M.C.-A., C.K.Z., M.J., Z.C., A.S., J.M.H.), Brigham and Women's Hospital, Harvard Medical School; Harvard T. H. Chan School of Public Health (M.C.-A., C.K.Z., M.J., Z.C., A.S., J.M.H.), Boston, Massachusetts; and Department of Surgery (C.K.Z.), Duke University Medical Center, Durham, North Carolina.
Leuk Res Rep
November 2024
Hematology Laboratory, Central laboratory, Mohammed VI University Hospital, Oujda, Morocco.
Introduction: Acute promyelocytic leukemia (AML-M3), classified as acute Myeloid leukemia with PML RARA according to the 5th edition of the World Health Organization classification of haematolymphoid tumors 2022 [1], is marked by abnormal promyelocyte proliferation and is known for high risks of bleeding and thromboembolic complications. We present a case where lower limb ischemia revealed this leukemia in a child.
Case Report: An 11-year-old with minor ankle trauma developed severe lower limb ischemia, leading to the discovery of subtotal femoral artery thrombosis.
Neurol India
November 2024
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Sporadic late-onset nemaline rod myopathy is a rare, acquired, sub-acute, adult-onset myopathy characterized by proximal muscle weakness and nemaline rods in the myofibers. In contrast to its congenital form, the prevalence in adult population is comparatively rare. Herein, we report a case of 60-year-old male who presented with insidious onset proximal muscle weakness with myopathic pattern on electromyography.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!